Sweeping federal transparency mandates will force pharmacy benefit managers to disclose complex fee structures, reshaping revenue models across the healthcare sector.

Cross-aisle convergence on prescription drug pricing, consumer credit protections, and industrial trade policy is establishing a new regulatory reality for corporate balance sheets.

Healthcare equities face shifting sentiment as institutional investors weigh drug pricing scrutiny, rising clinical costs, and M&A opportunities across the sector.